BTIG raises Climb Bio target to $20; Wedbush stays at $17
BTIG analyst Julian Harrison raised the price target for Climb Bio to $20 while maintaining a Buy rating. Separately, Wedbush analyst Laura Chico reiterated an Outperform rating with a $17 price target.
*this image is generated using AI for illustrative purposes only.
BTIG analyst Julian Harrison has maintained a Buy rating on Climb Bio (NASDAQ: CLYM) and raised the price target to $20, while Wedbush analyst Laura Chico reiterated an Outperform rating with a $17 price target. The divergent targets highlight varying perspectives on the company's stock performance potential among analysts.
Rating and Target Details
BTIG's revised price target of $20 represents an increase from the prior $19 level, signaling increased confidence. Meanwhile, Wedbush maintained its existing stance, keeping the target steady at $17.
| Firm | Analyst | Rating | Price Target |
|---|---|---|---|
| BTIG | Julian Harrison | Buy | $20 |
| Wedbush | Laura Chico | Outperform | $17 |
The recommendations from both firms remain positive, indicating an expectation of upside for Climb Bio.
What specific factors drove BTIG to increase confidence in Climb Bio's performance?
How might the market react to the divergent price targets from BTIG and Wedbush?
What upcoming catalysts could bridge the gap between the $17 and $20 price targets?
15
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
